TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE EUROPE THROAT CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET END USER COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 67
4.2 PORTERS FIVE FORCES 68
5 INDUSTRY INSIGHTS 69
6 EPIDEMIOLOGY 70
7 EUROPE THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 71
7.1 REGULATORY SCENARIO IN THE U.S 71
7.2 REGULATORY SCENARIO IN AUSTRALIA 72
7.3 REGULATORY SCENARIO IN JAPAN 72
7.4 REGULATORY SCENARIO IN CHINA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 GROWING PREVALENCE OF THROAT CANCER 76
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 76
8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 77
8.2 RESTRAINTS 77
8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 77
8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 77
8.3 OPPORTUNITIES 78
8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 78
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 79
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
8.4 CHALLENGES 80
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 80
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
9 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
9.1 OVERVIEW 82
9.2 INSTRUMENTS 85
9.2.1 PATHOLOGY-BASED INSTRUMENTS 86
9.2.1.1 PCR INSTRUMENTS 86
9.2.1.2 SLIDE STAINING SYSTEMS 86
9.2.1.3 TISSUE PROCESSING SYSTEMS 87
9.2.1.4 CELL PROCESSORS 87
9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
9.2.2 IMAGING INSTRUMENTS 87
9.2.2.1 ULTRASOUND SYSTEMS 87
9.2.2.2 CT SYSTEMS 87
9.2.2.3 MRI SYSTEMS 87
9.2.2.4 OTHERS 88
9.2.3 BIOPSY INSTRUMENTS 88
9.2.4 OTHERS 88
9.3 CONSUMABLES & ACCESSORIES 88
9.3.1 KITS 89
9.3.1.1 PCR KITS 89
9.3.1.2 DNA POLYMERASE KITS 89
9.3.1.3 NUCLEIC ACID ISOLATION KITS 89
9.3.1.4 OTHERS 90
9.3.2 REAGENTS 90
9.3.2.1 ASSAYS 90
9.3.2.2 BUFFERS 90
9.3.2.3 PRIMERS 90
9.3.2.4 OTHERS 90
9.3.3 PROBES 90
9.3.4 OTHER CONSUMABLES 90
10 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
10.1 OVERVIEW 92
10.2 IMAGING TEST 95
10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
10.2.2 MRI 96
10.2.3 CHEST X-RAY 96
10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 96
10.2.5 OTHERS 96
10.3 BLOOD TEST 96
10.3.1 BLOOD CHEMISTRY TESTS 98
10.3.2 COMPLETE BLOOD COUNT (CBC) 98
10.3.3 OTHERS 98
10.4 BIOPSY 98
10.4.1 ENDOSCOPIC BIOPSY 99
10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 99
10.4.3 OTHERS 99
10.5 OTHERS 100
11 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 101
11.1 OVERVIEW 102
11.2 PHARYNGEAL CANCER 105
11.2.1 NASOPHARYNGEAL CANCER 106
11.2.2 OROPHARYNGEAL CANCER 106
11.2.3 HYPOPHARYNGEAL CANCER 106
11.3 LARYNGEAL CANCER 107
12 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 108
12.1 OVERVIEW 109
12.2 STAGE III 112
12.3 STAGE II 112
12.4 STAGE IV 113
12.5 STAGE I 114
12.6 STAGE 0 115
13 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY AGE 116
13.1 OVERVIEW 117
13.2 30-65 120
13.3 65 AND ABOVE 121
13.4 21-29 121
13.5 BELOW 21 122
14 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY END USER 123
14.1 OVERVIEW 124
14.2 HOSPITALS 127
14.3 ASSOCIATED LABS 127
14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 128
14.5 DIAGNOSTIC IMAGING CENTERS 129
14.6 CANCER RESEARCH INSTITUTES 130
14.7 OTHERS 131
15 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 132
15.1 OVERVIEW 133
15.2 DIRECT TENDER 136
15.3 RETAIL SALES 137
16 EUROPE THROAT CANCER DIAGNOSTICS MARKET, BY REGION 138
16.1 EUROPE 139
16.1.1 GERMANY 149
16.1.2 FRANCE 154
16.1.3 U.K. 159
16.1.4 ITALY 164
16.1.5 SPAIN 169
16.1.6 RUSSIA 174
16.1.7 TURKEY 179
16.1.8 NETHERLANDS 184
16.1.9 BELGIUM 189
16.1.10 SWITZERLAND 194
16.1.11 REST OF EUROPE 199
17 EUROPE THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 200
17.1 COMPANY SHARE ANALYSIS: EUROPE 200
18 SWOT ANALYSIS 201
19 COMPANY PROFILE 202
19.1 F. HOFFMANN- LA ROCHE LTD 202
19.1.1 COMPANY SNAPSHOT 202
19.1.2 REVENUE ANALYSIS 202
19.1.3 COMPANY SHARE ANALYSIS 203
19.1.4 PRODUCT PORTFOLIO 203
19.1.5 RECENT DEVELOPMENT 203
19.2 FUJIFILM CORPORATION 204
19.2.1 COMPANY SNAPSHOT 204
19.2.2 REVENUE ANALYSIS 204
19.2.3 COMPANY SHARE ANALYSIS 205
19.2.4 PRODUCT PORTFOLIO 205
19.2.5 RECENT DEVELOPMENT 205
19.3 THERMO FISHER SCIENTIFIC INC. 206
19.3.1 COMPANY SNAPSHOT 206
19.3.2 REVENUE ANALYSIS 206
19.3.3 COMPANY SHARE ANALYSIS 207
19.3.4 PRODUCT PORTFOLIO 207
19.3.5 RECENT DEVELOPMENTS 207
19.4 CANON MEDICAL SYSTEMS CORPORATION 208
19.4.1 COMPANY SNAPSHOT 208
19.4.2 REVENUE ANALYSIS 208
19.4.3 COMPANY SHARE ANALYSIS 209
19.4.4 PRODUCT PORTFOLIO 209
19.4.5 RECENT DEVELOPMENT 209
19.5 KONINKLIJKE PHILIPS N.V. 210
19.5.1 COMPANY SNAPSHOT 210
19.5.2 REVENUE ANALYSIS 210
19.5.3 COMPANY SHARE ANALYSIS 211
19.5.4 PRODUCT PORTFOLIO 211
19.5.5 RECENT DEVELOPMENT 212
19.6 ABBOTT 213
19.6.1 COMPANY SNAPSHOT 213
19.6.2 REVENUE ANALYSIS 213
19.6.3 PRODUCT PORTFOLIO 214
19.6.4 RECENT DEVELOPMENTS 214
19.7 AGILENT TECHNOLOGIES, INC. 215
19.7.1 COMPANY SNAPSHOT 215
19.7.2 REVENUE ANALYSIS 215
19.7.3 PRODUCT PORTFOLIO 216
19.7.4 RECENT DEVELOPMENT 216
19.8 BD 217
19.8.1 COMPANY SNAPSHOT 217
19.8.2 REVENUE ANALYSIS 217
19.8.3 PRODUCT PORTFOLIO 218
19.8.4 RECENT DEVELOPMENTS 218
19.9 BEIJING O&D BIOTECH CO., LTD. 219
19.9.1 COMPANY SNAPSHOT 219
19.9.2 PRODUCT PORTFOLIO 219
19.9.3 RECENT DEVELOPMENT 219
19.10 BIO-RAD LABORATORIES, INC. 220
19.10.1 COMPANY SNAPSHOT 220
19.10.2 REVENUE ANALYSIS 220
19.10.3 PRODUCT PORTFOLIO 221
19.10.4 RECENT DEVELOPMENT 221
19.11 FONAR CORP. 222
19.11.1 COMPANY SNAPSHOT 222
19.11.2 REVENUE ANALYSIS 222
19.11.3 PRODUCT PORTFOLIO 223
19.11.4 RECENT DEVELOPMENT 223
19.12 GE HEALTHCARE 224
19.12.1 COMPANY SNAPSHOT 224
19.12.2 REVENUE ANALYSIS 224
19.12.3 PRODUCT PORTFOLIO 225
19.12.4 RECENT DEVELOPMENT 225
19.13 HOLOGIC INC. 226
19.13.1 COMPANY SNAPSHOT 226
19.13.2 REVENUE ANALYSIS 226
19.13.3 PRODUCT PORTFOLIO 227
19.13.4 RECENT DEVELOPMENT 227
19.14 ILLUMINA, INC. 228
19.14.1 COMPANY SNAPSHOT 228
19.14.2 REVENUE ANALYSIS 228
19.14.3 PRODUCT PORTFOLIO 229
19.14.4 RECENT DEVELOPMENT 229
19.15 MEDONICA CO. LTD 230
19.15.1 COMPANY SNAPSHOT 230
19.15.2 PRODUCT PORTFOLIO 230
19.15.3 RECENT DEVELOPMENT 230
19.16 MERCK KGAA 231
19.16.1 COMPANY SNAPSHOT 231
19.16.2 REVENUE ANALYSIS 231
19.16.3 PRODUCT PORTFOLIO 232
19.16.4 RECENT DEVELOPMENT 232
19.17 MINFOUND MEDICAL SYSTEMS CO., LTD 233
19.17.1 COMPANY SNAPSHOT 233
19.17.2 PRODUCT PORTFOLIO 233
19.17.3 RECENT DEVELOPMENT 233
19.18 MYRIAD GENETICS, INC. 234
19.18.1 COMPANY SNAPSHOT 234
19.18.2 REVENUE ANALYSIS 234
19.18.3 PRODUCT PORTFOLIO 235
19.18.4 RECENT DEVELOPMENT 235
19.19 PLEXBIO 236
19.19.1 COMPANY SNAPSHOT 236
19.19.2 PRODUCT PORTFOLIO 236
19.19.3 RECENT DEVELOPMENT 236
19.20 QIAGEN 237
19.20.1 COMPANY SNAPSHOT 237
19.20.2 REVENUE ANALYSIS 237
19.20.3 PRODUCT PORTFOLIO 238
19.20.4 RECENT DEVELOPMENT 238
19.21 QUEST DIAGNOSTICS INCORPORATED 239
19.21.1 COMPANY SNAPSHOT 239
19.21.2 REVENUE ANALYSIS 239
19.21.3 PRODUCT PORTFOLIO 240
19.21.4 RECENT DEVELOPMENT 240
19.22 SIEMENS HEALTHCARE GMBH 241
19.22.1 COMPANY SNAPSHOT 241
19.22.2 REVENUE ANALYSIS 241
19.22.3 PRODUCT PORTFOLIO 242
19.22.4 RECENT DEVELOPMENT 242

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.